Novavax Stock Fair Value Calculator – Is Novavax Stock a Sell After Failed Covid Shot Attempts?
December 11, 2023
🌧️Trending News
Novavax ($NASDAQ:NVAX) is a clinical-stage biotechnology company that specializes in the development of vaccines to prevent a wide range of infectious diseases.
However, recent news about the failure of its Phase 3 clinical trial has caused many investors to question whether they should sell their Novavax stock. Unfortunately, the results of its Phase 3 clinical trial showed that the vaccine was not as effective as hoped, leading to a sharp drop in the company’s stock price. This has caused many investors to reconsider their investments and whether they should sell their Novavax stock. Despite the setback, it is important to note that Novavax continues to move forward with its vaccine development. The company is currently conducting additional trials to further improve the efficacy of its vaccine and is still optimistic that it can eventually achieve success. Furthermore, Novavax still has a strong financial position, giving it the resources to continue its vaccine development efforts. Ultimately, the decision whether to sell Novavax stock depends on each individual’s risk profile and financial goals. While the failed trial is certainly disappointing, investors should consider all factors before making a decision about whether to sell their shares.
Share Price
Monday proved to be a difficult day for NOVAVAX stock, which opened at $5.8 and closed at $5.7 – a 0.5% decrease from the previous closing price of $5.7. This drop comes as a result of the failed attempts to develop a coronavirus vaccine, leaving investors concerned about the company’s future prospects. This has caused investors to question whether NOVAVAX is worth investing in at this time. Novavax_Stock_a_Sell_After_Failed_Covid_Shot_Attempts”>Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Novavax. More…
| Total Revenues | Net Income | Net Margin |
| 973.73 | -548.92 | -56.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Novavax. More…
| Operations | Investing | Financing |
| -655 | -71.79 | 95.52 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Novavax. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.66k | 2.34k | -5.71 |
Key Ratios Snapshot
Some of the financial key ratios for Novavax are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 68.2% | – | -55.0% |
| FCF Margin | ROE | ROA |
| -74.6% | 46.8% | -20.2% |
Analysis – Novavax Stock Fair Value Calculator
GoodWhale has conducted an analysis of NOVAVAX’s wellbeing to gain a better understanding of its intrinsic value. According to our proprietary Valuation Line, the intrinsic value of NOVAVAX share is around $48.3. However, the current market price of NOVAVAX stock is only $5.7, meaning it is being traded at 88.2% below its actual value. Our analysis provides evidence that NOVAVAX is currently undervalued and may be an attractive investment opportunity. Novavax_Stock_a_Sell_After_Failed_Covid_Shot_Attempts”>More…
Peers
The competition between Novavax Inc and its competitors is fierce. Moderna Inc, BioNTech SE, and Pfizer Inc are all major players in the vaccine industry, and each company is striving to develop the most effective vaccine possible. While Novavax Inc has made great strides in recent years, its competitors are not far behind.
– Moderna Inc ($NASDAQ:MRNA)
Moderna Inc is a clinical stage biotechnology company that discovers, develops, and commercializes therapeutics and vaccines based on RNA. As of 2022, Moderna Inc has a market cap of 48.32B and a ROE of 80.28%. Moderna Inc’s mission is to harness the power of RNA to revolutionize medicine and change the way diseases are prevented, treated, and cured.
– BioNTech SE ($NASDAQ:BNTX)
As of 2022, BioNTech SE has a market cap of 32.44B and a Return on Equity of 71.82%. The company is a German biotechnology company that develops and manufactures vaccines and antibody therapeutics. The company has developed a platform that allows it to rapidly design and produce custom-made vaccines and therapeutics.
– Pfizer Inc ($NYSE:PFE)
Pfizer Inc is a pharmaceutical company with a market cap of 247.45B as of 2022. The company has a return on equity of 24.63%. Pfizer Inc is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets safe, effective, and affordable human and veterinary medicines. The company is one of the world’s largest research-based pharmaceutical companies, with products available in more than 150 countries.
Summary
However, analysts note that the company’s long-term fundamentals remain uncertain, as its vaccine candidate has not yet met the necessary safety and efficacy requirements for a licensure. As such, investors should be cautious when considering investing in NOVAVAX until the company’s vaccine candidate advances through clinical trials. Additionally, investors should also keep an eye on the company’s financials as its research and development expenses are likely to remain high until a licensure is achieved.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
